ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.
